Financial reports

"The first quarter of 2026 accelerated Cereno Scientific’s transition into the next stage of clinical development. We advanced preparations for the global Phase IIb trial with CS1 in pulmonary arterial hypertension (PAH), progressed CS014 through a streamlined pathway toward Phase IIb, and continued strengthening our scientific and strategic position within rare cardiopulmonary diseases. As multiple near-term milestones approach, we are increasingly focused on execution, operational readiness and continued value creation across the pipeline."